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The ﬁeld of hepatology, like all medical disciplines, has greatly
beneﬁted from the development of model systems. These include
cell culture models (primary cells and cell lines), disease and
genetic models in ﬁsh, rodents and higher organisms, and math-
ematical models in humans. Three studies in this issue of Journal
of Hepatology nicely illustrate the power and pitfalls of model sys-
tems in advancing our understanding of human liver disease.
The study by Dubuquoy et al. examines the regulation of the
PNPLA3 gene (also called ‘adiponutrin’), by two important meta-
bolic rheostats, the transcription factors SREBP-1c and ChREBP,
which regulate lipid and carbohydrate metabolism, respectively.
PNPLA3 was uncovered as an important clue to the pathogenesis
of non-alcoholic fatty liver disease when a single nucleotide poly-
morphism, or sequence variant, was uncovered that is strongly
associated with risk of NAFLD [7], and more recently with alco-
holic liver disease as well [10]. The initial association was discov-
ered through a genome-wide association study, underscoring the
strength of this unbiased large scale screening technique to dis-
cover hidden links to disease pathogenesis from genes not on
the investigative radar. In the case of the PNPLA3 risk variant,
the mechanism for conferring risk of disease by the SNP remains
uncertain, but the variant protein lacks the ability to hydrolyze
triglycerides to the same extent as the wild type protein [2].
The Dubuquoy study does not examine the role the PNPLA3
SNP, but instead attempts to position the protein within the con-
text of known metabolic mediators by examining its regulation
by SREPB-1c and ChREBP. To do so, the studies rely primarily
on a mouse model in which PNPLA3 gene expression is tracked
in mice following either dietary or genetic manipulation of lipid
and carbohydrate homeostasis. Studies were also conducted in
isolated mouse hepatocytes, and thereafter in immortalized
human hepatocytes in culture. One problem with this approach,
however, is that the pattern of PNPLA3 expression differs signif-
icantly between mouse and man, wherein mice have very low
expression in normal liver while humans have high hepatic
expression [6]. Indeed, the authors discovered that hepatic
PNPLA3 is regulated by ChREBP in mouse but not in man. More-
over, most of the analyses rely on mRNA expression, even though
there is signiﬁcant post-translational regulation of PNPLA3
stability.Journal of Hepatology 20
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human disease? Not necessarily, and in fact the species difference
in PNPLA3 regulation could represent a clue to the difference
between rodent models of fatty liver disease and the human con-
dition. However, failure to recognize the limitation of the rodent
model could have led to over-extrapolation of its results to
humans. Moreover, even the human experiments in this report
are limited to two immortalized cell lines, so the models used
are informative but not ideal, and the ﬁndings must still be vali-
dated in a more relevant human system.
The study by Lu et al. adds a different wrinkle to the use of
animal models, in this case to study hepatocellular carcinoma
(HCC). The authors generated a very clever in vivo reporter sys-
tem to detect the emergence of early HCC in mice by combined
bioluminescence and PET imaging. To accomplish this goal, they
inserted two reporter constructs – luciferase for bioluminescence
detection and thymidylate kinase for PET imaging – downstream
of the promoter for alpha fetoprotein (AFP) in the germline of
knock-in mice to express these reporter genes in early HCC cells,
which typically re-express AFP as they become cancerous. Using
this approach, early tumor formation could be imaged in animals
given diethylnitrosamine (DEN), a standard HCC-inducing toxin
[4], without having to sacriﬁce the mice. This strategy enabled
the investigators to study the kinetics of HCC development in real
time. So in this example, disease dynamics rather than molecular
mechanisms are the focus of their modeling effort. Still, the
model could be combined with different genetically altered mice
that lack or over-express candidate HCC related genes in order to
interrogate the contributions of speciﬁc pathways.
Interestingly, other elements of disease modeling are also rep-
resented by the Lu study. First, DEN is the mostly widely used
method to generate HCC in mice. However, the tumors in this
model arise in a non-ﬁbrotic background, which is not represen-
tative of human HCCs, and, moreover, they lack the marked
molecular heterogeneity that is typical of human HCC [1]. Second,
the genetic background is a critical determinant of HCC develop-
ment after DEN, and thus the investigators were required to
backcross their mice from the C57Bl/6j-129Sv strain into the
FVC3H background to facilitate tumor development. While in
humans the presence of chronic liver disease and not host genet-
ics is the most compelling risk for HCC development, it is also
clear that host genetic determinants contribute to disease risk
as well. For example, a polymorphism in the epidermal growth
factor gene has been linked to HCC risk among patients with cir-
rhosis [9]. Thus, the Lu study nicely illustrates not only a model11 vol. 55 j 1–2
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that employs novel imaging technology, but also the features of
an experimental model of chemical carcinogenesis, as well as a
model for genetic inﬂuences on cancer development.
The third study by Drumright et al. exploits a different type of
modeling – mathematical modeling – to explore predictors and
effects of alcohol use on liver function tests in injection drug
users with HCV infection. Speciﬁcally, part of their analysis relies
on Markov modeling, a statistical method that models medical
prognosis for clinical problems with ongoing risk [8]. The inves-
tigators have examined the impact of behavioral intervention
on alcohol use in this population and linked this intervention to
changes in liver function tests. The synergistic effect of excessive
alcohol on ﬁbrosis progression in chronic HCV is well known [5],
and thus any intervention that might reduce alcohol use is worth
considering in order to slow ﬁbrosis progression. By exploiting
the strengths of Markov modeling, the investigators reached sev-
eral important conclusions. First, marijuana use, itself a determi-
nant of accelerated ﬁbrosis progression [3], also increased the
return to alcohol use among those who had been abstinent. Sec-
ond, effective intervention to stop alcohol use led to an improve-
ment in serum transaminases, demonstrating for the ﬁrst time a
clear, positive impact on disease severity through behavioral
intervention in this population. While the results may not be
entirely surprising, they nonetheless reinforce the value of inter-
vention efforts to reduce morbidity from alcohol use, which in
the United States costs in excess of $185 million per year
(http://www.niaaa.nih.gov/Resources/DatabaseResources/Quick-
Facts/EconomicData/Pages/cost8.aspx). Importantly, the conclu-
sions might not have emerged without the application of
sophisticated modeling.
What do these three studies tell us with regard to models in
liver disease? It is axiomatic to suggest that all models have
strengths and weaknesses. Yet, from the data from each model
emerges a thread that together weaves a tapestry of a human
liver disease.2 Journal of Hepatology 2Conﬂict of interest
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